União Europeia - maltês - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analġeżiċi - ziconotide huwa indikat għall-kura ta 'uġigħ sever u kroniku f'pazjenti li jeħtieġu analġeżija intrateġika (it).

União Europeia - maltês - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunosoppressanti - crohn diseasestelara huwa indikat għall-kura ta 'pazjenti adulti b'attiva minn moderata sa gravi marda ta' crohn li kellhom rispons inadegwat b', tilfu r-rispons għal, jew li kienu intolleranti jew terapija konvenzjonali jew tnfa antagonista jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn. kolite colitisstelara huwa indikat għall-kura ta ' pazjenti adulti b'attiva minn moderata sa gravi kolite bl-ulċeri li kellhom rispons inadegwat b', tilfu r-rispons għal, jew li kienu intolleranti jew terapija konvenzjonali jew bijoloġika jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn. plakka psoriasisstelara huwa indikat għall-kura moderata għal severa ta ' psorjasi tal-plakka f'adulti li naqsu milli jirrispondu għal, jew li għandhom kontraindikazzjoni għal, jew li huma intolleranti għal terapiji sistemiċi oħrajn inkluż ciclosporin, methotrexate u psoralen ultraviolet-a. pedjatrika tal-plakka psoriasisstelara huwa indikat għall-kura moderata għal severa ta 'psorjasi tal-plakka fit-tfal u pazjenti adolexxenti mill-età ta' 6 snin u akbar, li huma kkontrollati b'mod inadegwat minn, jew li huma intolleranti għal, terapiji jew fototerapiji sistemiċi oħrajn. psorjatika arthritisstelara, waħdu jew f'taħlita ma 'methotrexate, huwa indikat għall-kura ta' artrite psorjatika attiva f'pazjenti adulti meta r-rispons għall-preċedenti mhux bijoloġika li jimmodifikaw il-marda anti-rewmatiċi tad-droga (dmard) it-terapija kienet inadegwata.

União Europeia - maltês - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. għal aktar informazzjoni dwar l-istatus tal-fattur tat-tkabbir tal-epidermide tal-bniedem 2 (her2), jekk jogħġbok irreferi għat-taqsima 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. għal aktar informazzjoni dwar l-istatus ta 'her2, jekk jogħġbok irreferi għat-taqsima 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

União Europeia - maltês - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. għal aktar informazzjoni dwar l-istatus tal-fattur tat-tkabbir tal-epidermide tal-bniedem 2 (her2), jekk jogħġbok irreferi għat-taqsima 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. għal aktar informazzjoni dwar l-istatus ta 'her2, jekk jogħġbok irreferi għat-taqsima 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

União Europeia - maltês - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazole - schizophrenia; bipolar disorder - psikolettiċi - abilify huwa indikat għat-trattament tal-iskiżofrenja fl-adulti u fl-adolexxenti ta '15-il sena jew ikbar. abilify huwa indikat għat-trattament ta 'episodji manijaċi serji f'disturb bipolari i u għall-prevenzjoni ta' episodju manijaku ġdid f'adulti li esperjenzaw episodji predominantament manijaċi u li l-episodji manijaċi rrispondew għat-trattament b'aripiprazole. abilify huwa indikat għat-trattament sa 12-il ġimgħa ta 'episodji manijaċi serji f'disturb bipolari i fl-adolexxenti ta' minn 13-il sena u anzjani.

União Europeia - maltês - EMA (European Medicines Agency)

accord healthcare s.l.u. - aripiprazole - schizophrenia; bipolar disorder - psikolettiċi - aripiprazole qbil huwa indikat għat-trattament ta'l-iskizofrenija fl-adulti u fl-adoloxxenti ta'bejn il-15-il sena u anzjani. aripiprazole qbil huwa indikat għat-trattament ta 'episodji manijaċi serji f'disturb bipolari i u għall-prevenzjoni ta' episodju manijaku ġdid f'adulti li esperjenzaw episodji predominantament manijaċi u li l-episodji manijaċi rrispondew għat-trattament b'aripiprazole. aripiprazole qbil huwa indikat għall-kura sa 12-il ġimgħa ta 'episodji manijaċi serji f'disturb bipolari i fl-adolexxenti ta' minn 13-il sena u anzjani.

União Europeia - maltês - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - edarbi huwa indikat għat-trattament tal-ipertensjoni essenzjali fl-adulti.

União Europeia - maltês - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. imprida huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

União Europeia - maltês - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - sklerosi multipla - immunosuppressanti selettivi - lemtrada huwa indikat għall-pazjenti adulti bl-relapsing-remitting multipli sclerosis (rrms) bil-marda attiva definiti mill-karatteristiċi kliniċi jew tal-immaġnar.

União Europeia - maltês - EMA (European Medicines Agency)

shionogi b.v. - ospemifene - postmenopause - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.